Clinical Trial Update: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. [Phase 4]

View source ↗

Summary

This Phase 4 trial update describes extending ibrutinib treatment for patients who continue to benefit from the therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma
• Graft-versus-host Disease
• Non-hodgkin Lymphoma
• Solid Tumor

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Pharmacyclics Switzerland GmbH | Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin | Phase 4 | Status: ACTIVE_NOT_RECRUITING